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Abstract
Background—An estimated 1.2 million American adults engage in sexual and drug use 
behaviors that place them at significant risk of acquiring HIV infection. Engagement in health care 
for the provision of daily oral antiretroviral medication as preexposure prophylaxis (PrEP), when 
clinically indicated, could substantially reduce the number of new HIV infections in these persons. 
However, resources to cover the financial cost of PrEP care is an anticipated barrier for many of 
the populations with high numbers of new HIV infections.
Methods—Using nationally representative data, we estimated the current national met and unmet 
need for financial assistance with covering the cost of PrEP medication, clinical visits, and 
laboratory costs among adults with indications for its use, overall and by transmission risk 
population.
Results—This study found that, of the 1.2 million adults estimated to have indications for PrEP 
use, <1% (∼7,300) are in need of financial assistance for both PrEP medication and clinical care, 
at an estimated annual cost of $89 million. An additional 7% (∼86,300) are in need of financial 
assistance only for PrEP clinical care at an estimated annual cost of $119 million.
Conclusion—This information on PrEP care costs, insurance coverage, and unmet financial 
need among persons in key HIV transmission risk subpopulations can inform policy makers at all 
levels as they consider how to address remaining financial barriers to the use of PrEP and 
accommodate any changes in eligibility for various insurance and financial assistance programs 
that may occur in coming years.
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Introduction
The Centers for Disease Control and Prevention (CDC) estimates that 1.2 million persons in 
the United States have sexual or injection behaviors that place them at substantial risk of 
acquiring HIV infection.1 These adults would benefit from the use of daily oral antiretroviral 
prophylaxis (PrEP) which has been proven both safe and highly effective in reducing HIV 
infections for gay, bisexual and other men who have sex with men (MSM), heterosexually 
active females and males (HET), and persons who inject drugs not prescribed to them 
(PWID). The FDA approved PrEP as an indication for daily co-formulated tenofovir 
disoproxil fumarate and emtricitabine (brand name Truvada) in 2012 and CDC issued 
clinical practice guidelines for PrEP in 2014.2 The affordability of medication, laboratory 
testing, and clinical care visits required for the safe prescription and monitoring of PrEP is a 
critical issue for its access by those who would benefit from its use. PrEP is being 
implemented in the United States at the same time as changes in the health care insurance 
landscape resulting from the Patient Protection and Affordable Care Act (ACA) enacted in 
2010. Several studies have found that the anticipation of high cost is a barrier to the 
acceptability of PrEP use as an HIV prevention method.3,4 However in one study of 30 
financially disadvantage PrEP users in Mississippi5, all had successfully accessed PrEP 
despite initial perceived concerns about costs. “While many participants noted that they had 
initially perceived the high cost of PrEP as a potential barrier to use, those barriers were 
overcome with the industry sponsored medication assistance program, which pays for PrEP 
for uninsured patients and provides assistance with medication copayments for insured 
individuals”. The one participant who stopped PrEP because they lost their job and 
insurance did not know about the medication assistance program. Although anticipated 
concerns about coverage of PrEP costs have been widely discussed online,6 no published 
studies to document the scale of the problem were available so we assessed the extent to 
which insurance and PrEP assistance plans will meet the anticipated need.
Methods
Population inputs
Data from national population-based surveys were analyzed to estimate the percentages and 
numbers of persons with indications for PrEP as previously described1. Using the same 
population-based surveys, we estimated the percentages and number of persons with PrEP 
indications by insurance type and federal poverty level for each of the three major HIV 
transmission risk populations, MSM, HET, and PWID. Insurance type was categorized 
hierarchically into private insurance, public insurance, and no health insurance coverage. For 
MSM and HET, public insurance included Medicare, Medicaid, Medi-Gap, Indian Health 
Service, SCHIP, military health care (Champus, Champ/VA), state-sponsored health plan, 
and other government insurance and no health insurance was defined as the absence of 
private or public insurance or insured by only a single payer.7,8 For PWID, public insurance 
included Medicare, Medicaid, Medi-Gap, SCHIP, military health care (Champus, 
Champ/VA) or other insurance and no health insurance was the absence of private or public 
insurance.9 Federal poverty level was categorized into the estimated percentage and number 
of persons with household federal poverty level less than 500% or greater than or equal to 
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500%. The National Health and Examination Survey (NHANES) and National Survey of 
Family Growth (NSFG) already produce a calculated variable allowing federal poverty level 
to be grouped by both our definitions7,8. The National Survey on Drug Use and Health 
(NSDUH) does not report federal poverty level by the percentage ranges we defined. So to 
obtain estimates for PWID, we recalculated federal poverty level based on the U.S. Census 
Bureau's Poverty Thresholds for 2013 by Size of Family and Number of Related Children 
Under 18 Years, using the weighted average threshold since NSDUH does not include the 
number of children and size of family unit in their public release dataset.10 Lastly, the 
percentage of uninsured persons ineligible for coverage due to immigration status, and 
uninsured persons in the coverage gap, were based on the Kaiser Family Foundation report, 
‘The Uninsured: A Primary’.11
Cost inputs
The costs of PrEP medication, clinical visits, and laboratory costs were identified from 
various sources. The Red Book was used to identify the 2016 average wholesale price for a 
30 day supply of Truvada.12 The estimated 340B pricing is equal to 51% of the average 
wholesale price.13 The costs of clinical visits for the first year on PrEP were based on 
estimates reported by the American Medical Association for specified visit CPT billing 
codes.14 Lastly, laboratory costs for tests recommended for the first year a person is taking 
PrEP were based on the Health Care Blue Book15 and personal communication on Federally 
Qualified Health Center (FQHC) cost for 4th generation HIV test through a major 
commercial laboratory (Table 1).
Estimating persons with PrEP indications in need of assistance for all PrEP medication 
and care or PrEP care only
Figure 1 illustrates the logic of the analysis used to identify persons in need of financial 
assistance for PrEP care. For each transmission risk group, the health insurance status was 
identified as described above. For persons who had private or public insurance, based on 
reports from recent observational studies, we assumed that 1% of persons may have 
coverage for PrEP denied by their insurance and were therefore in need of assistance (2a). 
For persons who were uninsured, we then estimated that 15% of persons were 
undocumented (2b) and 10% of persons were living in a state that did not expand Medicaid 
coverage (2c).11 These persons were not eligible for traditional Medicaid or ACA 
marketplace subsidies (in the coverage gap) and therefore in need of assistance. For persons 
who had private or public insurance coverage, we estimated the percentage and number who 
had insurance coverage that did cover PrEP care; these persons were not considered in need 
of assistance (3a). For persons who were uninsured, we estimated the percentage and 
number who were documented and not in the coverage gap, these persons were not 
considered in need of assistance (3b).
Of those identified as in need of assistance, some persons could obtain medication at no cost 
through the Medication Assistance Program (MAP) offered by Gilead Sciences to uninsured 
US residents whose household federal poverty level was less than 500%. By insurance 
coverage, we estimated the percentage of persons that had a federal poverty level less than 
500% and identified those persons as in need of financial assistance for the cost of clinical 
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visits and laboratory tests (PrEP care) if they obtained medication through Gilead's MAP 
(4a). Those with a federal poverty level greater than or equal to 500% were not eligible for 
Gilead's MAP and therefore in need of financial assistance for the costs of medication, 
clinical visits, and laboratory tests (i.e., all PrEP medication and care) (4b).
Costs for medication, clinical visits and laboratory costs were calculated by transmission 
risk population when recommendations varied by group. Laboratory costs varied by 
transmission category and sex and included four HIV antibody tests, one 4th generation HIV 
test, 2 basic metabolic panels, 1 pregnancy test (females only), 1 hepatitis B serology test, 5 
syphilis tests for MSM and 2 syphilis tests for the other transmission risk groups, and 15 
nucleic acid amplification tests for gonorrhea and chlamydia (NAAT GC/CT) for MSM and 
2 for the other transmission risk groups per year (Table 1b).
Based on the estimated number of persons by transmission risk category in need of financial 
assistance for all PrEP medication and care or for PrEP care but not medication, we 
estimated the cost per transmission risk group and the estimated total number of persons and 
cost if a payor of last resort program were to pay for medication, clinical visits, or laboratory 
tests among persons with indications for PrEP use who were uninsured or whose insurers 
denied coverage for PrEP.
Sensitivity analyses estimating the effect of varying two key inputs were conducted. The first 
sensitivity analysis accounted for the variability in the estimated number of persons with 
indications for PrEP by transmission risk group. We estimated lower and upper bound inputs 
by calculating the midpoint between the point estimate (Table 1) and the 95% confidence 
intervals; i.e., [point estimate – ((point estimate – lower 95% confidence interval)/2)].1 The 
second sensitivity analysis accounted for the variability in the estimated percentage of 
persons in households with federal poverty level less than 500% by insurance coverage. 
Again, we estimated the lower and upper bound inputs by calculating the midpoint between 
the point estimate and the associated 95% confidence intervals (not reported).
Results
Our analyses of population-based survey data for 2015 estimates that of adults with PrEP 
indications, 64% of MSM had private insurance, 11% had public insurance, and 25% were 
uninsured; 49% and 51% of heterosexual females and heterosexual males respectively had 
private insurance, 27% and 20% had public insurance, and 24% and 29% were uninsured; 
while among PWID, 21% had private insurance, 29% had public insurance, and 50% were 
uninsured (Figure 2). The percentage of adults with PrEP indications living at a federal 
poverty level <500% varied by transmission risk category and insurance coverage (Table 1).
An estimated 50,800 persons with PrEP indications (Table 2) were undocumented US 
residents, comprising 15% of the uninsured. An estimated 36% of undocumented persons 
with PrEP indications were MSM, 34% were heterosexual females, 13% were heterosexual 
males, and 17% were PWID. An estimated 33,900 persons with PrEP indications were in the 
coverage gap, comprising 10% of the uninsured.
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The estimated number of MSM, heterosexual females, heterosexual males, and PWID with 
indications for PrEP in need of any financial assistance is shown in Table 2. Based on the 
analysis algorithm (Figure 1), an estimated 34,200 MSM (7%) are in need of PrEP payment 
assistance, 30,500 of whom are uninsured. An estimated 32,000 (7%) heterosexual females 
are in need of PrEP payment assistance, 28,400 of whom are uninsured. An estimated 
12,400 heterosexual males (8%) are in need of PrEP payment assistance, 11,300 of whom 
are uninsured. An estimated 15,000 PWID (13%) are in need of PrEP payment assistance, 
14,500 of whom are uninsured.
The estimated number of persons in need of financial assistance for both PrEP medications 
and associated health care (Table 3) was 2,600 MSM, 3,500 heterosexual females, 100 
PWID females, 1000 heterosexual males and 100 PWID males. In all transmission risk 
group populations, the number in need was <1% of those with indications for PrEP use. At 
Medicaid reimbursement rates for clinical care and 340B pricing for meds, the estimated 
annual cost of PrEP medications and care per person was $12,913 for MSM, $11,711 for 
heterosexual and PWID females, and $11,694 for heterosexual and PWID males.
The estimated number of persons in need of financial assistance for PrEP care alone (for 
clinical visits and laboratory tests but not PrEP medication), was 31,700 MSM, 28,500 
heterosexual females, 7,000 PWID females, 11,400 heterosexual males and 7,000 PWID 
males. At Medicaid reimbursement rates for clinical care (including laboratory tests), the 
estimated annual cost of PrEP care per person was $2,143 for MSM, $941 for heterosexual 
and PWID females, and $924 for heterosexual and PWID males.
The average wholesale price of Truvada was $1,759.73,16 while the estimated 340B price 
available to many federally funded clinics was $897.46.13 Clinical visit costs summed to 
$422.21 for the first year for all persons with PrEP indications. At FQHC prices (Table 3), 
the cost of PrEP medication was 89% of costs in the first year of care, labs were 8%, and 
charges for clinical care visits were 3%.
Across all transmission risk group populations, an estimated 7,300 persons are in need of 
assistance for both PrEP medication and care, with an estimated annual cost of $88.9 
million. In addition, 83,300 persons are in need of assistance for PrEP care only, with an 
estimated annual cost of $119.0 million. Of the 1.2 million adults with PrEP indications, less 
than 1% are in need of financial assistance for both PrEP medication and care and 7% are 
need of assistance for PrEP care only.
Sensitivity analyses found that using the calculated lower and upper bound inputs for the 
estimated number of persons with PrEP indications as described above, the number of 
persons in need of financial assistance ranged from 68,900 to 118,300 persons resulting in a 
range of annual costs of $153.3 million to $262.5 million. Using the calculated lower and 
upper bound inputs for the estimated percentage of persons in households with federal 
poverty level less than 500%, the number of persons in need of financial assistance remained 
the same (93,600) with estimated annual costs ranging from $177.6 million to $243.8 
million.
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Discussion
To inform ongoing discussions about supporting financial access to PrEP medication and 
associated health care for persons at substantial risk of HIV acquisition, it is important to 
have a measure of the extent of coverage already available and the size of the population in 
need of additional resources. We obtained these estimates by applying nationally 
representative data on public and private insurance coverage; and for the uninsured, data on 
household income, and criteria for eligibility for ACA insurance or the pharmaceutical PrEP 
medication assistance plan to a prior assessment of the number of persons with indications 
for PrEP use in the United States.1
In summary, we found that few persons with indications for PrEP use have an entirely unmet 
need for financial coverage of medication and/or associated clinical care costs. Of persons 
estimated to have indications for its use, 75% of MSM, 76% of Het females, 71% of Het 
males, and 50% of PWID have public or private insurance to cover most PrEP care costs. Of 
those who are privately insured, an unknown proportion are eligible for medication co-pay 
assistance (<500% FPL) from Gilead Sciences17 or the Patient Advocates Foundation 
(<400% FPL).18
An estimated 75% of those who are uninsured are eligible by income for ACA insurance 
through federal or state exchanges. Of those with no access to private, public, or ACA 
insurance, 92% are eligible by household income for PrEP medication at no cost through the 
Gilead Medication Assistance Plan (MAP).17 These persons will benefit from insurance 
navigation services to enroll in ACA or other healthcare insurance for which they are 
eligible, or assistance to enroll in the Gilead MAP if not insurable. In addition, PrEP has 
been nominated for review by the US Preventive Services Task Force. If it receives an A or 
B rating as a recommended preventive service, some cost elements may be reduced for those 
with health insurance.
Less than 1% of persons with indications for PrEP are not insured, not eligible for ACA 
insurance, and ineligible for MAP, resulting in an entirely unmet need for financial 
assistance for all elements of PrEP care. Many of these persons can receive subsidized care 
through sliding fee schedules at FQHCs and other safety-net clinics, but will still have 
problems with drug costs that may be prohibitive. For them, a number of solutions are being 
considered or have been implemented, including state PrEP assistance plans (payor of last 
resort plans), some of which cover only the medication19, and some of which cover only the 
clinicial visit and lab costs.20
In all cases, navigation and linkage to PrEP care services by community workers, social 
workers, nurses, or others will aid in having more people with indications for its use aware 
of PrEP and able to access the necessary clinical care to receive it. Equally important, 
financial benefits navigation for all PrEP patients to ensure that they retain all coverage 
benefits as their employment status, income, residence, or other life circumstances change 
will be critical to retention in PrEP care and protective levels of medication adherence. Loss 
of insurance coverage leading to medication non-adherence has been associated with 
acquisition of HIV infection in cohorts of PrEP patients.21
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The national cost of covering PrEP for all persons with indications for its use in need of 
assistance is significant, an estimated $208 million annually, including both those who need 
help with clinical care costs only, ($119 million) and those who need help with both 
medication and clinical care costs ($89 million). For comparison, the FY16 federal budget 
allocates 19.7 billion dollars for treatment and health care for persons already living with 
HIV infection, approximately 75% of the domestic funding for HIV.22 In addition, while 
there is evidence that PrEP uptake is increasing rapidly in some locations23-25 particularly 
among MSM, there are only estimated to be about 80,000 persons who were prescribed 
PrEP in 2012-2015 nationwide26 or approximately 6% of the number who we estimate 
would benefit from its use. At current rates of uptake, it will be some time before all persons 
in need of financial assistance are attempting to access PrEP services.
Another key concern is that PrEP is not currently accessed equitably in the geographic areas 
(e.g., the southern US) and subpopulations (e.g., young African American MSM and 
women) experiencing the most severe disparities in rates of new HIV infections.27 Given our 
analysis and the current financial burden in some subpopulations, existing inequities are 
likely to be exacerbated, especially among undocumented persons who are ineligible for 
most forms of federally-funded health insurance.
There are several limitations of the analysis that merit consideration. While we are unaware 
of any insurance, public or private, that has a formal policy not to cover PrEP care, we have 
used an estimate of 1% non-coverage to allow for the likelihood that we are unaware of the 
few plans that do not cover it, as well as the unknown proportion of coverage that is declined 
in error (i.e., despite no formal policy of non-coverage). This may be overestimating the 
number of insured persons who need financial assistance. There is a complex array of 
deductibles, co-pay, and coinsurance rates that apply to the range of insurance options 
depending on the level of plan chosen. Within each level, some plans have deductible limits 
for medications separate from the limit for all other expenses; some have a deductible for 
each individual in a family separate from the deductible for the family as a whole. This 
analysis does not include these potential out-of-pocket costs explicitly, although we do use 
income to assess eligibility for co-pay/co-insurance assistance and experience to date 
suggests that residual costs are affordable for most.
There are at least three areas where public health systems can leverage opportunities to 
support provision of PrEP as a clinical HIV prevention service: 1) linking clinical and 
community prevention, 2) supporting the development of alternative payment methodologies 
to cover community-based and clinical prevention services, and 3) using epidemiologic 
knowledge to ensure access to PrEP for populations at highest risk of HIV acquisition. 
Public health has a key role in developing and reinforcing systems to provide clinical and 
community prevention services.28
Conclusion
PrEP is an important new tool for HIV prevention and its expanded use is supported by 
several federal agency efforts, including the National HIV/AIDS Strategy. The FDA-
approved use of Truvada for PrEP has been widely available for four years, but many people 
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who can benefit from PrEP aren't yet being prescribed it. The causes for this are varied, but 
concern is frequently raised about the costs of the daily medication, and the ongoing 
periodic clinical visits and laboratory testing recommended by the Public Health Service 
(PHS) clinical practice guidelines issued by CDC to ensure its safe and effective use. This 
study found that a small number of patients would not be financially covered for their 
clinician visits and laboratory tests, and an even smaller number would have no coverage for 
medication, as well as the clinical costs of PrEP care. If the eligibility for different types of 
insurance, medication or co-pay assistance programs changes substantially in coming years, 
it will impact the financial feasibility of scaling up PrEP use to the many who would benefit 
from its use. This information on PrEP care costs, insurance coverage, and unmet financial 
need among persons in key HIV transmission risk subpopulations can inform policy makers 
at all levels as they consider how to begin addressing remaining financial barriers to the use 
of PrEP in their communities as part of a renewed effort to decrease the number of new HIV 
infections in the United States.
Acknowledgments
We thank Laura Eastham for her thoughtful comments on early drafts.
Funding: No external funding was used to support this study
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
References
1. Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: Estimated percentages and numbers of 
adults with indications for preexposure prophylaxis to prevent HIV acquisition–United States, 2015. 
Morbidity and Mortality Weekly Report. 2015; 64(46):1291–1295. [PubMed: 26606148] 
2. Centers for Disease Control and Prevention. [Accessed May 28, 2014] US Public Health Service. 
Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014: a clinical 
practice guideline; 2014. p. 1-67.http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf
3. Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes, and likelihood of pre-exposure 
prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDS. 2015; 
29(2):102–110. [PubMed: 25513954] 
4. Perez-Figueroa RE, Kapadia F, Barton SC, Eddy JA, Halkitis PN. Acceptability of PrEP Uptake 
Among Racially/Ethnically Diverse Young Men Who Have Sex With Men: The P18 Study. AIDS 
Educ Prev. 2015; 27(2):112–125. [PubMed: 25915697] 
5. Arnold T, Brinkley-Rubinstein L, Chan PA, et al. Social, structural, behavioral and clinical factors 
influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi. PloS one. 2017; 
12(2):e0172354. [PubMed: 28222118] 
6. Project Inform. Financing and Delivery Mechanisms to Increase Pre-Exposure Prophylaxis (PrEP) 
Access in Populations at High-Risk of HIV Infection. 2011. http://www.projectinform.org/pdf/PrEp
%20Financing%20Report.pdf
7. Centers for Disease Control and Prevention. [Accessed November 9, 2016] National Health and 
Nutriotion Examination Survey. 2015. http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm
8. Centers for Disease Control and Prevention. [Accessed November 9, 2016] National Survey of 
Family Growth. 2015. http://www.cdc.gov/nchs/nsfg/nsfg_questionnaires.htm
9. Substance Abuse and Mental Health Services Administration. [Accessed November 9, 2016] 
National Survey on Drug Use and Health. 2015. http://www.samhsa.gov/data/population-data-nsduh
Smith et al. Page 8
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 December 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
10. Census Bureau, US. [Accessed July 7, 2016] Poverty Thresholds for 2013 by Size of Family and 
Number of Related Children Under 18 Years. 2016. https://www.census.gov/data/tables/time-
series/demo/income-poverty/historical-poverty-thresholds.html
11. Kaiser Family Foundation. [Accessed July 7, 2016] The Uninsured: A Primer. 2015. http://
files.kff.org/attachment/primer-the-uninsured-a-primer-key-facts-about-health-insurance-and-the-
uninsured-in-the-era-of-health-reform
12. Truven Health Analytics. [Accessed July 7, 2016] Red Book. 2016. http://micromedex.com/
products/product-suites/clinical-knowledge/redbook
13. Congressional Budget Office. [Accessed June 12, 2016] Prices for Brand-Name Drugs Under 
Selected Federal Programs. 2005. http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/64xx/
doc6481/06-16-prescriptdrug.pdf
14. American Medical Association. [Accessed July 7, 2016] CPT Code/Relative Value Search Tool. 
2016. https://www.ama-assn.org/practice-management/find-coding-resources
15. CAREOperative. [Accessed July 7, 2016] Healthcare Bluebook. 2016. https://
healthcarebluebook.com/page_Default.aspx
16. Panel on Antiretroviral Guidelines for Adults and Adolescents. [Accessed June 12, 2016] 
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Department 
of Health and Human Services Cost Considerations and Antiretroviral Therapy. Guidelines for the 
Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2016. https://
aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/459/cost-considerations-
and-antiretroviral-therapy
17. Gilead Sciences. Programs are available that may help lower the cost of TRUVADA for PrEP. 
2016. https://start.truvada.com/paying-for-truvada
18. Patient Advocate Foundation. Co-Pay Relief. 2016. https://www.copays.org/diseases/hiv-aids-and-
prevention
19. Washington State Department of Health. [Accessed 12 June 2016] Pre-Exposure Prophylaxis Drug 
Assistance Program (PrEP DAP). 2014. http://www.doh.wa.gov/YouandYourFamily/
IllnessandDisease/HIVAIDS/HIVCareClientServices/PrEPDAP
20. New York State AIDS Institute. [Accessed June 12, 2016] Pre-Exposure Prophylaxis Assistance 
Program (PrEP-AP). 2015. https://www.health.ny.gov/diseases/aids/general/resources/adap/
prep.htm
21. Marcus JL, Hurley LB, Hare CB, et al. Preexposure Prophylaxis for HIV Prevention in a Large 
Integrated Health Care System: Adherence, Renal Safety, and Discontinuation. JAIDS Journal of 
Acquired Immune Deficiency Syndromes. 2016; 73(5):540–546. [PubMed: 27851714] 
22. Kaiser Family Foundation. [Accessed June 12, 2016] Fact Sheet: U.S. Federal Funding for HIV/
AIDS: Trends Over Time. 2016. http://kff.org/global-health-policy/fact-sheet/u-s-federal-funding-
for-hivaids-trends-over-time/
23. Laufer FN, O'Connell DA, Feldman I, Mps, Zucker HA. Vital Signs: Increased Medicaid 
Prescriptions for Preexposure Prophylaxis Against HIV infection--New York, 2012-2015. MMWR 
Morb Mortal Wkly Rep. 2015; 64(46):1296–1301. [PubMed: 26606257] 
24. Hood JE, Buskin SE, Dombrowski JC, et al. Dramatic increase in preexposure prophylaxis use 
among MSM in Washington state. AIDS. 2016; 30(3):515–519. [PubMed: 26562845] 
25. Chen YH, Snowden JM, McFarland W, Raymond HF. Pre-exposure Prophylaxis (PrEP) Use, 
Seroadaptation, and Sexual Behavior Among Men Who Have Sex with Men, San Francisco, 2004–
2014. AIDS and Behavior. 2016:1–7. [PubMed: 26370101] 
26. Mera R, MS., Palmer, B., Mayer, G., Magnuson, D., Rawlings, K. FTC/TDF (Truvada) for HIV 
Pre-Exposure Prophylaxis (PrEP) Utilization in the United States: 2012-2015. 2016. http://
programme.aids2016.org/PAGMaterial/PPT/5404_11614/Mera%20TVD%20PrEP%20utilization
%20IAC%202016%20FINAL.pptx
27. Bush S, MD., Rawlings, M., Hawkins, T., McCallister, S., Mera-Giler, R. American Society for 
Microbiology 2016. Boston, MA: Jun 16-20. 2016 Racial Characteristics of FTC/TDF for Pre-
Exposure Prophylaxis Users in the US. 2016
Smith et al. Page 9
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 December 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
28. O'Connor JC, Gutelius BJ, Girard KE, Drum Hastings D, Longoria L, Kohn MA. Paying for 
prevention: a critical opportunity for public health. The Journal of law, medicine & ethics : a 
journal of the American Society of Law, Medicine & Ethics. 2013; 41(1):69–72.
Smith et al. Page 10
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 December 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Diagram of Analysis Algorithm
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Figure 2. 
Coverage Status by Transmission Risk Group, ACA - Affordable Care Act; HET - 
heterosexually active persons; MAP – Medication Assistance Program; MSM = men who 
have sex with men; PWID = persons who inject drugs
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